Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept®

On August 5, 2016 Lantern Pharma, Inc. (Dallas, TX, US) and BioNumerik Pharmaceuticals, Inc. of San Antonio, Texas reported that they have entered into an exclusive agreement for Lantern Pharma to evaluate BioNumerik’s Tavocept for human therapeutic indications using Lantern’s 5-M theranostic platform (Press release, Lantern Pharma, AUG 5, 2016, View Source [SID1234564256]). Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology indications. Lantern Pharma is a Precision Oncology Medicine company focused on using its proprietary 5-M platform to identify specific drug sensitivity signatures for patient tumor types. The Tavocept transaction demonstrates Lantern’s commitment to the development of precision cancer drugs by employing its cutting-edge companion 5-M theranostics platform with the objective of providing more precise and therefore more effective treatments to patients sooner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Arun Asaithambi of Lantern Pharma, commented: "We believe Lantern Pharma’s approach can be successfully applied to identify new value opportunities for drug candidates with promising potential that have encountered development challenges. We are excited about Tavocept and the potential to enhance its therapeutic potency through the application of our 5-M approach."

"We believe Tavocept has important potential to be of benefit to patients, and we are excited to be working with Lantern Pharma to examine possible ways to realize and expand that potential," said Thomas W. Lyles, Jr., President of BioNumerik Pharmaceuticals, Inc.